Enesi Pharma, a clinical-stage company developing unique injectable solid dose drug-device combination products, announces its launch as a new company at the World Vaccine Congress, which takes place on 10-12 October in Barcelona, Spain.
Enesi is focused on the development of innovative vaccines and therapeutics using its proprietary ImplaVax™ technology, which have the potential to make a material impact on global healthcare.
ImplaVax is the combination of an innovative and proprietary solid dose formulation and device technology for subcutaneous vaccination offering significant potential benefits for patients, care givers, healthcare professionals and payers. Product benefits are achieved through enhanced effectiveness, safety, ease of use, reliability and stability. ImplaVax products also offer no risk of needle-stick injury or transmission of disease, and are supported by a strong patient preference over needle and syringe.
Enesi Pharma’s primary focus is the development of novel solid dose vaccines against a range of infectious and other select diseases, its technologies have undergone thorough feasibility testing, and the ImplaVax device is approved for human clinical trial use. Data delivered to date demonstrated that ImplaVax enabled vaccines can deliver a superior immune response compared to standard injection protocols and retain potency across a wide range of storage conditions for prolonged periods, without the need for point-of-care reconstitution, thereby minimising or eliminating cold-chain requirements.
Led by CEO David Hipkiss, Enesi Pharma’s management team has a proven track record in the development and commercialisation of innovative products delivering high value outcomes for all stakeholders. Alongside COO Andy Bush, David co-founded Prosonix, a private UK company that successfully developed a range of novel, particle-engineered respiratory medicines which was subsequently acquired by Circassia for £100m in 2015. They are complemented by new Non-Executive Chairman, Meinhard Schmidt, a diagnostics industry executive and entrepreneur with more than 25 years’ broad international experience ranging from global general, operations, marketing and innovation management.
David Hipkiss, CEO of Enesi Pharma, said:
“We are delighted to announce the Company’s launch today at the World Vaccine Congress. Our novel ImplaVax™ technology offers a potential step change in innovation offering enhanced immune response, safety and convenience as we strive towards fulfilling our vision of ‘Immunity for Life’. As we apply our platform to a range of high value antigen and vector targets to address serious diseases, the benefits are evident, manifest and clear. I am excited about the Enesi team’s ability to bring new products to patients and make a material impact on global healthcare.”
The company’s new website is available at www.enesipharma.com